CORCEPT THERAPEUTICS INC (CORT) Form 10-Q — Nov 3, 2026
Corcept Therapeutics reported Q3 2026 net product revenue of $340.5 million, up 64% from $207.6 million a year ago, with net income of $126.8 million versus $19.7 million in Q3 2025 and diluted EPS of $1.01 versus $0.16. The launch of Lifyorli (relacorilant), FDA-approved in March 2026 for platinum-resistant ovarian cancer, contributed $91.4 million of Q3 revenue, while the legacy Hypercortisolism franchise grew to $249.1 million on volume, pricing, and improved payor reimbursement. The company holds $662.3 million in cash and marketable securities, generated $159.7 million in operating cash flow over nine months, and says it needs no additional funding for at least 12 months.
Key figures
- Eps
- 1.01
- Revenue
- 340472000
- Net Income
- 126778000
- Revenue Yoy
- 64% (Q3 2026 vs Q3 2025)
- Total Assets
- 1034027000
- Cash Position
- 662300000
- Shares Outstanding
- 109443109
- Retained earnings
- 781391000
- Nine month revenue
- 761522000
- Lifyorli q3 revenue
- 91405000
- Stock repurchase q3
- 5745000
- Nine month net income
- 138004000
- Nine month diluted eps
- 1.13
- Prior year q3 net income
- 19668000
- Prior year q3 diluted eps
- 0.16
- Hypercortisolism q3 revenue
- 249067000
- Operating cash flow nine months
- 159662000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.